Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Literature DB >> 2543994

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

Abstract

This article describes the antiviral properties of foscarnet (trisodium phosphonoformate) at the enzyme level as well as in cell cultures and in vivo. The mechanism of action against herpesvirus DNA polymerases and reverse transcriptases is outlined. Clinical studies using topical foscarnet against mucocutaneous herpes simplex virus infections are presented. The clinical use of intravenous foscarnet against severe viral infections caused by cytomegalovirus, hepatitis B virus and human immunodeficiency virus is discussed.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1989 PMID： 2543994 DOI： 10.1016/0163-7258(89)90097-1

Source DB: PubMed Journal: Pharmacol Ther ISSN： 0163-7258 Impact factor: 12.310

Keyword Cloud
Cited

39 in total

1. Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.

Authors: A M Taburet; C Katlama; C Blanshard; G Zorza; D Gazzard; E Dohin; B G Gazzard; C Frostegard; E Singlas
Journal: Antimicrob Agents Chemother Date: 1992-09 Impact factor: 5.191

Review 2. Screening for new agents.

Authors: B Oberg; L Vrang
Journal: Eur J Clin Microbiol Infect Dis Date: 1990-07 Impact factor: 3.267

9. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Authors: J W Mellors; H Z Bazmi; R F Schinazi; B M Roy; Y Hsiou; E Arnold; J Weir; D L Mayers
Journal: Antimicrob Agents Chemother Date: 1995-05 Impact factor: 5.191

10. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.

Authors: T Cihlar; M D Fuller; J M Cherrington
Journal: J Virol Date: 1998-07 Impact factor: 5.103

Antiviral effects of phosphonoformate (PFA, foscarnet sodium).

1. Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.

Review 2. Screening for new agents.

Review 3. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Review 4. Antiviral therapy: current concepts and practices.

5. Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.

6. Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease.

Review 7. Management of CMV retinitis in HIV infected patients.

Review 8. Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

9. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

10. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments.